Frölich L. EU - Europäische Union : Supple Graphene Bio-Platform for point-of-care early detection and monitoring of Alzheimer's Disease. 10/2023-09/2027.
Hausner L. Roche Pharma AG : TRONTINEMAB: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, PARALLEL-Group Efficacy and safety study of Trontinemab in Participants with early symptomatic Alzheimer´s Disease (MCI to mild dementia due to ad) WN45443 or WN45447. 01/2026.
Hausner L. : ALTITUDE-AD: A Phase 2/3 Double-Blind, Randomized, Placebo-Controlled Adaptive Design Trial to Evaluate the Efficacy and Safety of Intravenous ACU193 in Early Alzheimer’s Disease. 01/2025.
Hausner L. : Clarity-AD: A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study with an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects with Early Alzheimer’s Disease. 01/2020.
